Last updated on May 2019

Safety and Efficacy of TRx0237 in Subjects With Early Alzheimer's Disease


Brief description of study

The purpose of this study is to determine the safety and efficacy of TRx0237 8 mg/day and 16 mg/day in the treatment of subjects with early Alzheimer's Disease compared to placebo.

Clinical Study Identifier: NCT03446001

Find a site near you

Start Over